Your browser doesn't support javascript.
loading
Poliovirus serological assay after the cVDPV1 outbreak in Papua New Guinea: a cross-sectional study from 2020 to 2021.
Pomat, William; Lopez Cavestany, Rocio; Jeyaseelan, Visalakshi; Ford, Rebecca; Gare, Janet; Avagyan, Tigran; Grabovac, Varja; Bettels, Deborah; Mekonnen, Dessie; Jones, Kathryn Ann Vetter; Mainou, Bernardo Alfredo; Mach, Ondrej.
Afiliación
  • Pomat W; Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
  • Lopez Cavestany R; Polio Eradication Department, World Health Organization Headquarters, Geneva, Switzerland.
  • Jeyaseelan V; Polio Eradication Department, World Health Organization Headquarters, Geneva, Switzerland.
  • Ford R; Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
  • Gare J; Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
  • Avagyan T; World Health Organization, Western Pacific Regional Office, Manila, Philippines.
  • Grabovac V; World Health Organization, Western Pacific Regional Office, Manila, Philippines.
  • Bettels D; World Health Organization, Papua New Guinea Country Office, Port Moresby, National Capital District, Papua New Guinea.
  • Mekonnen D; World Health Organization, Papua New Guinea Country Office, Port Moresby, National Capital District, Papua New Guinea.
  • Jones KAV; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mainou BA; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mach O; Polio Eradication Department, World Health Organization Headquarters, Geneva, Switzerland.
Lancet Reg Health West Pac ; 44: 100986, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38204497
ABSTRACT

Background:

In June 2018, a type 1 circulating vaccine-derived poliovirus (cVDPV1) outbreak was declared in Papua New Guinea (PNG), resulting in a total of 26 paralytic confirmed cases. Eight vaccination campaign rounds with bivalent oral poliovirus vaccine (bOPV) were carried out in response. Prevalence of neutralizing polio antibodies in children was assessed two years after the outbreak response was completed.

Methods:

We conducted a cross-sectional serological survey among children aged 6 months-10 years selected from six provinces in PNG to evaluate seroprevalence of neutralizing polio antibodies to the three poliovirus serotypes and analyse sociodemographic risk factors.

Findings:

We included 984 of 1006 enrolled children in the final analysis. The seroprevalence of neutralizing polio antibodies for serotype 1, 2 and 3 was 98.3% (95% CI 97.4-98.9), 63.1% (95% CI 60.1-66.1) and 95.0% (95% CI 93.6-96.3), respectively. Children <1 year had significantly lower type 1 seroprevalence compared to older children (p < 0.001); there were no significant differences in seroprevalence among provinces.

Interpretation:

PNG successfully interrupted transmission of cVDPV1 with several high coverage bOPV campaigns and seroprevalence remained high after two years. The emergence of cVDPV strains underscores the importance of maintaining high levels of routine immunization coverage and effective surveillance systems for early detection.

Funding:

World Health Organization through a Rotary International IPPC grant.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Lancet Reg Health West Pac Año: 2024 Tipo del documento: Article País de afiliación: Papúa Nueva Guinea

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies / Screening_studies Idioma: En Revista: Lancet Reg Health West Pac Año: 2024 Tipo del documento: Article País de afiliación: Papúa Nueva Guinea